Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

(RTTNews) - Flare Therapeutics has entered into a strategic discovery collaboration with Roche. The partnership will leverage Flare Therapeutics' proteomic and mass spectrometry platform, to discover ...